Redeye provides a first comment following Ngenic's release of its Q1 report.
Sales -3% vs. ABGSCe ACV growth of 7% q-o-q Guides for SEK 650m 2023e revenue Q1'23 results Qlosr’s...
Northern CapSek Ventures (”CapSek”) rapport för det första kvartalet visade en stabil tillväxt för d...
Redeye updates its estimates following Imint’s Q1 2023 report and the press release on May 24, regar...
Serneke delivered a mixed set of numbers for Q1, with the group EBIT margin slightly below our expec...
Redeye comments on Lipigon’s first-quarter report. After the end of Q1, all patients in the phase I ...
Gullberg & Jansson redovisade en minskad omsättning, EBIT och vinst jämfört med Q1’22.
Scandinavian Astor Group meddelade den 24 maj att styrelsen har beslutat att utreda förutsättningarn...
Redeye provides an update post Embracers Q4 2022/23 results.
STENOCARE announced on May 25th, that a new medical cannabis oil product has received approval from ...
Mangold ser positivt på att ADDvise uppdaterat sina långsiktiga finansiella mål.
Redeye is surprised by the news that an advisory panel has suggested changed classification of I-Tec...
Syncro Group (alt. ”Koncernen”) presenterade nyligen sin Q1-rapport vilken visade hög tillväxt under...
Redeye states that Strax Q1’23 report was weak on top line but with better profitability The sales ...
Redeye states that ChromoGenics Q1’23 report was overall better than expected despite soft top line.
Redeye endorses yesterday’s news that Alzecure has presented positive phase IIa data with ACD440 in ...
Raute is set to complete its equity injections during the next few weeks.
Redeye provides an update on Adverty following its Q1 2023 report.
Redeye comments on InDex Pharmaceuticals following its Q1 2023 report.
Redeye updates on Better Collective following its Q1-results where the company reached record revenu...
